CA3072867A1 - Method - Google Patents

Method Download PDF

Info

Publication number
CA3072867A1
CA3072867A1 CA3072867A CA3072867A CA3072867A1 CA 3072867 A1 CA3072867 A1 CA 3072867A1 CA 3072867 A CA3072867 A CA 3072867A CA 3072867 A CA3072867 A CA 3072867A CA 3072867 A1 CA3072867 A1 CA 3072867A1
Authority
CA
Canada
Prior art keywords
peptide
subject
disease
seq
myelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3072867A
Other languages
English (en)
French (fr)
Inventor
Keith Martin
Liselotta JANSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Worg Pharmaceuticals Zhejiang Co Ltd
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713035.2A external-priority patent/GB201713035D0/en
Priority claimed from GBGB1713037.8A external-priority patent/GB201713037D0/en
Priority claimed from GBGB1713036.0A external-priority patent/GB201713036D0/en
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of CA3072867A1 publication Critical patent/CA3072867A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3072867A 2017-08-14 2018-08-14 Method Pending CA3072867A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1713036.0 2017-08-14
GBGB1713035.2A GB201713035D0 (en) 2017-08-14 2017-08-14 Method
GB1713037.8 2017-08-14
GB1713035.2 2017-08-14
GBGB1713037.8A GB201713037D0 (en) 2017-08-14 2017-08-14 Method
GBGB1713036.0A GB201713036D0 (en) 2017-08-14 2017-08-14 Method
PCT/GB2018/052304 WO2019034862A1 (en) 2017-08-14 2018-08-14 Method

Publications (1)

Publication Number Publication Date
CA3072867A1 true CA3072867A1 (en) 2019-02-21

Family

ID=63294371

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072867A Pending CA3072867A1 (en) 2017-08-14 2018-08-14 Method

Country Status (8)

Country Link
US (1) US20210093695A1 (https=)
EP (1) EP3668535A1 (https=)
JP (1) JP7419229B2 (https=)
CN (1) CN111225681A (https=)
AU (2) AU2018316662A1 (https=)
CA (1) CA3072867A1 (https=)
WO (1) WO2019034862A1 (https=)
ZA (1) ZA202000882B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111983241B (zh) * 2020-09-04 2022-05-20 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法
WO2023100758A1 (ja) * 2021-11-30 2023-06-08 国立大学法人京都大学 ペプチド含有組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
AU2008320657B2 (en) * 2007-10-31 2013-09-05 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Composition
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201300683D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10759838B2 (en) * 2015-03-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use

Also Published As

Publication number Publication date
JP2020530846A (ja) 2020-10-29
WO2019034862A1 (en) 2019-02-21
ZA202000882B (en) 2023-08-30
JP7419229B2 (ja) 2024-01-22
CN111225681A (zh) 2020-06-02
AU2025201115A1 (en) 2025-03-06
US20210093695A1 (en) 2021-04-01
EP3668535A1 (en) 2020-06-24
AU2018316662A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
AU2025201115A1 (en) Method
JP5361895B2 (ja) 組成物
JP2013100313A (ja) Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
JP2024544512A (ja) 嗜癖およびその再発に対する抵抗におけるポリペプチドの使用ならびに複合体およびポリペプチド
JP7591017B2 (ja) 寛容原性ペプチドを用いた治療方法
JP2024520952A (ja) 免疫原性ペプチドを使用した改善された処置方法
JP2020519627A (ja) 神経保護および再ミエリン化のための可溶性ｃｄ２４の使用方法
CN102802654A (zh) 用于脉络膜新生血管形成的疫苗疗法
JP2023532882A (ja) レット症候群の処置のためのセマフォリン４ｄ結合分子の使用
ES2370957T3 (es) Composiciones que comprenden péptidos de la proteína básica de la mielina y sus utilizaciones médicas.
HK40016470B (en) Therapeutic method using dose escalation protocol for tolerogenic peptides
HK40016470A (en) Therapeutic method using dose escalation protocol for tolerogenic peptides
HK40062599A (en) Methods and compositions for increasing neurogenesis and angiogenesis
HK1142803B (en) Compositions comprising myelin basic protein peptides and medical uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230814

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240826

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250614

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250614

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250804

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250804

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251202

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260401

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260402

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260402